© Reuters. FILE PHOTO: The logo of Sanofi is seen a the French drugmaker's vaccine unit Sanofi Pasteur plant in Marcy-l'Etoile, near Lyon, France, September 30, 2023. REUTERS/Gonzalo Fuentes/File PhotoDeliberations are ongoing and there is no certainty they will result in an agreement, the report said, adding that Mirati could also attract interest from other suitors.
The U.S. health regulator had in December approved Mirati's lung cancer drug, Krazati, to treat adults with advanced lung cancer. In November last year, Bloomberg had reported that Mirati was drawing takeover interest from large pharmaceutical companies.
این خبر را خلاصه کرده ایم تا بتوانید سریع آن را بخوانید. اگر به خبر علاقه مند هستید، می توانید متن کامل را اینجا بخوانید. ادامه مطلب: